Low fasting methionine concentration as a novel risk factor for recurrent venous thrombosis
Miranda B. A. J. Keijzer1, Martin den Heijer1, 2, George F. Borm2, Henk J. Blom3, Stein Emil Vollset4, Ad R. M. M. Hermus1, Per M. Ueland4
1Department of Endocrinology, 2Department of Epidemiology and Biostatistics, 3Laboratory of Paediatrics and Neurology, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands; 4Locus for Homocysteine and Related Vitamins, University of Be
Summary
Hyperhomocysteinemia is a risk factor for venous thrombosis, but the underlying mechanism is unclear. If the thiol-group of homocysteine interferes with components of the clotting system, we expect that high cysteine will be also a risk factor for venous thrombosis. If high homocysteine reflects a disturbed methyl-group donation by S-adenosylmethionine, we expect that low methionine will be a risk factor for thrombosis. We performed a case-control study in 185 patients with recurrent venous thrombosis and in 500 control subjects. We determined methionine, homocysteine, cysteine and assessed the associated thrombotic risk. Low fasting methionine was associated with an increased risk on recurrent venous thrombosis [ORbottom vs. top quartile = 3.3 (95%CI 1.9–5.7)]. Low methionine remained a risk factor [ORbottom vs. top quartile= 3.5 (95%CI 2.0–6.0)] after adjusting for homocysteine and cysteine, whereas the thrombotic risk for homocysteine was lost [OR= 1.0 (95%CI 0.6–1.9)] after adjustment. Cysteine yielded a highest odds ratio of 2.1top vs. bottom quartile (95%CI 1.0–4.0) after adjustment. In conclusion, we found that low fasting methionine is a risk factor for recurrent venous thrombosis.This risk association was stronger for methionine than for homocysteine or cysteine.This supports the hypothesis that impaired methylation may be involved in the pathogenesis of venous thrombosis. Keywords
Venous thrombosis, homocysteine, Methionine, cysteine
DOI
http://dx.doi.org/10.1160/TH06-04-0187